Results are gradual and tied to consistent use, often paired with lifestyle adjustments
[15] [39] [40] In August 2025, the Food and Drug Administration (FDA) expanded the indication for semaglutide (as Wegovy) to include the treatment of noncirrhotic metabolic-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults
Semaglutide is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus, not requiring formal dose tapering when discontinued
Curious about how semaglutide might fit into your weight loss journey
However, always get your doctor's approval before combining treatments
While tirzepatide reduces appetite and calorie intake, L-carnitine theoretically optimizes fat oxidation during the calorie deficit that results